banner add

Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices

In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, the drugmaker Amgen has aggressively blocked competition for it.

from NYT > Health https://ift.tt/NWShtOr
via IFTTT

No comments

Genetic Data From Over 20,000 U.S. Children Misused for ‘Race Science’

The National Institutes of Health failed to protect brain scans that an international group of fringe researchers used to argue for the inte...

Theme images by PLAINVIEW. Powered by Blogger.